Transformative Healthcare Instrument 2026

Closed

Programme Category

EU Competitive Programmes

Programme Name

Funding under projects

Programme Description

Funding provided under previews programmes.

Programme Details

Identifier Code

EIT Health 26-28

Call

Transformative Healthcare Instrument 2026

Summary

The Transformative Health Instrument (THI) call invites micro, small, and medium enterprises (SMEs) to submit applications for funding to support the development of scalable health technologies in Biotech, Medtech, Digital Health & AI, Biomarker/Diagnostics or a combination of these. Applicants should address unmet needs in Europe with novel and commercially viable approaches, scientific excellence, and strong internal capabilities.

Detailed Call Description

This call aims to strengthen integration between the research and business sides of the knowledge triangle by accelerating healthcare innovations borne out of research to support commercial and business growth of small and micro enterprises in European markets. All funded projects under this Call are expected to generate the following outcomes and long-term impact.

  • Commercial acceleration, including attracting additional funding, closing future venture capital investments, and growing revenue (where applicable).
  • Developing and accelerating new health innovations with high potential to positively impact the lives of the citizens of Europe, as well as to generate financial returns.
  • Protection of new innovations and micro, small, and medium enterprises (SME ́s) via intellectual property (IP) strategy.

Call Total Budget

€5.000.000

Financing percentage by EU or other bodies / Level of Subsidy or Loan

Projects may request between € 300 000 and € 500 000 in EIT Health funding.

EIT Health will fund a maximum of 50% of the project’s total costs. The company must secure the remaining 50% co-funding from other sources.

The expected duration of participation is 12 months (January 2027-December 2027).

Thematic Categories

  • Health
  • Information and Communication Technologies
  • Information Technology
  • Research, Technological Development and Innovation
  • Small-Medium Enterprises and Competitiveness

Eligibility for Participation

  • Businesses
  • Legal Entities
  • Other Beneficiaries
  • Researchers/Research Centers/Institutions
  • Small and Medium Enterprises (SMEs)

Eligibility For Participation Notes

The call is intended to support private companies, specifically Micro, Small and Medium-sized enterprises (SMEs), with at least 4 full-time equivalent employees. Eligible companies must have closed a minimum total equity investment of €2.000.000  within the previous 36-months, with at least one new investor contributing.

In accordance with the Horizon Europe Work Programme, to be eligible for funding, the applicant must be established in one of the eligible countries, i.e.:

  • the Member States of the European Union, including their outermost regions;
  • the Overseas Countries and Territories (OCTs) linked to the Member States;
  • countries associated to Horizon Europe;  or,
  • certain low- and middle-income countries.

Companies should be focused on innovations within the healthcare sector, specifically Biotech, Medtech, Digital Health & AI, Biomarker/Diagnostics or a combination of these.

Funded projects must be at the Innovation Maturity Levels (IML) listed below, depending on their industry focus:

  • IML ≥ 5 for Biotech (Safety/Toxicity study stage).
  • IML≥ 6 in Medtech (Initial clinical PoC)
  • IML ≥ 7 for Digital (Market validation)
  • IML ≥ 7 for Biomarker / Diagnostics

Call Opening Date

15/07/2026

Call Closing Date

16/09/2026

EU Contact Point